
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
We demonstrate the wide range of customized products and services that Actylis offers its biopharma customers.






